Home NDC 84651-200-93 IBTROZI
Product NDC 84651-200
Requested package NDC 84651-200-93
11-digit product format 846510200
Labeler code 84651
Product ID 84651-200_12274fa4-44f0-4e87-9683-67b1515ea180
Type HUMAN PRESCRIPTION DRUG
Nonproprietary name taletrectinib
Dosage form CAPSULE
Route ORAL
Labeler Nuvation Bio Inc.
Application NDA219713
Marketing category NDA
Marketing start 2025-06-11
Substance TALETRECTINIB ADIPATE
Active strength 272 mg/1
Pharmacologic classes Kinase Inhibitor [EPC], Proto-Oncogene Tyrosine-Protein Kinase ROS1 Inhibitors [MoA]
NDC exclude flag No
Listing certified through 2027-12-31
Current FDA listing Yes Source provenance: Browse the complete Orange Book source catalog · source snapshot 45 .
Orange Book products# Current product rows page 1 of 1 · 1 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date N219713-001 IBTROZI TALETRECTINIB ADIPATE EQ 200MG BASE CAPSULE / ORAL RLD, RS 2025-06-11
Orange Book patents# Current patent rows page 1 of 1 · 2 matching rows.
Application-product, Patent, Expiration table Application-product Patent Expiration Use code Coverage / status Submission date N219713-001 9187489 2033-06-03 U-4207 Drug substance, Drug product 2025-06-27 N219713-001 9751887 2033-06-03 U-4207 Drug substance, Drug product 2025-06-27
Orange Book exclusivity# Current exclusivity rows page 1 of 1 · 2 matching rows.
Application-product, Exclusivity code, Expiration table Application-product Exclusivity code Expiration N219713-001 NCE 2030-06-11 N219713-001 ODE-544 2032-06-11
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2026-11-14 07:37:17 2026-10 N219713-001 IBTROZI EQ 200MG BASE CAPSULE / ORAL RLD, RS 2025-06-11 d4dbc9d85df4…2026-10-15 13:18:30 2026-09 N219713-001 IBTROZI EQ 200MG BASE CAPSULE / ORAL RLD, RS 2025-06-11 c2088c7a36db…2026-09-14 22:38:34 2026-08 N219713-001 IBTROZI EQ 200MG BASE CAPSULE / ORAL RLD, RS 2025-06-11 84e616aacf4f…2026-08-18 06:07:40 2026-07 N219713-001 IBTROZI EQ 200MG BASE CAPSULE / ORAL RLD, RS 2025-06-11 caaa826d4ba7…2026-02-19 14:30 UTC 2026-02 N219713-001 IBTROZI EQ 200MG BASE CAPSULE / ORAL RLD, RS 2025-06-11 011fe1cb6892…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N219713-001 IBTROZI EQ 200MG BASE CAPSULE / ORAL RLD, RS 2025-06-11 31067a03dcf5…2025-08-23 18:47 UTC 2025-08 N219713-001 IBTROZI EQ 200MG BASE CAPSULE / ORAL RLD, RS 2025-06-11 6a471c1ec25d…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N219713-001 IBTROZI EQ 200MG BASE CAPSULE / ORAL RLD, RS 2025-06-11 a50c72e98297…
Observed Orange Book patent history# Captured, Edition, Application-product table Captured Edition Application-product Patent Expiration Use code Coverage / status Submission date Source SHA-256 2026-11-14 07:37:17 2026-10 N219713-001 9187489 2033-06-03 U-4207 Drug substance, Drug product 2025-06-27 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N219713-001 9751887 2033-06-03 U-4207 Drug substance, Drug product 2025-06-27 d4dbc9d85df4…2026-10-15 13:18:30 2026-09 N219713-001 9187489 2033-06-03 U-4207 Drug substance, Drug product 2025-06-27 c2088c7a36db…2026-10-15 13:18:30 2026-09 N219713-001 9751887 2033-06-03 U-4207 Drug substance, Drug product 2025-06-27 c2088c7a36db…2026-09-14 22:38:34 2026-08 N219713-001 9187489 2033-06-03 U-4207 Drug substance, Drug product 2025-06-27 84e616aacf4f…2026-09-14 22:38:34 2026-08 N219713-001 9751887 2033-06-03 U-4207 Drug substance, Drug product 2025-06-27 84e616aacf4f…2026-08-18 06:07:40 2026-07 N219713-001 9187489 2033-06-03 U-4207 Drug substance, Drug product 2025-06-27 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N219713-001 9751887 2033-06-03 U-4207 Drug substance, Drug product 2025-06-27 caaa826d4ba7…2026-02-19 14:30 UTC 2026-02 N219713-001 9187489 2033-06-03 U-4207 Drug substance, Drug product 2025-06-27 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N219713-001 9751887 2033-06-03 U-4207 Drug substance, Drug product 2025-06-27 011fe1cb6892…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N219713-001 9187489 2033-06-03 U-4207 Drug substance, Drug product 2025-06-27 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N219713-001 9751887 2033-06-03 U-4207 Drug substance, Drug product 2025-06-27 31067a03dcf5…2025-08-23 18:47 UTC 2025-08 N219713-001 9187489 2033-06-03 U-4207 Drug substance, Drug product 2025-06-27 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N219713-001 9751887 2033-06-03 U-4207 Drug substance, Drug product 2025-06-27 6a471c1ec25d…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N219713-001 9187489 2033-06-03 U-4207 Drug substance, Drug product 2025-06-27 a50c72e98297…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N219713-001 9751887 2033-06-03 U-4207 Drug substance, Drug product 2025-06-27 a50c72e98297…
Observed Orange Book exclusivity history# Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.
Additional Listing Data#
Finished product Yes
Brand name base IBTROZI
Listing expiration 2027-12-31 Active Ingredients# Ingredient, Strength table Ingredient Strength TALETRECTINIB ADIPATE 272 mg/1
Harmonized UNII identifiers# UNII identifiers page 1 of 1 · 1 matching rows.
Identifier, FDA.report destination table Identifier FDA.report destination 6KLL51GNBG Internal UNII lookup
Harmonized RxCUI identifiers# RxCUI identifiers page 1 of 1 · 2 matching rows.
Identifier, FDA.report destination table Identifier FDA.report destination 2716925 Internal RxNorm lookup 2716931 Internal RxNorm lookup
Harmonized SPL set identifiers# SPL set identifiers page 1 of 1 · 1 matching rows.
DailyMed Product Concepts# DailyMed Package Descriptions# Package NDC, Product, Description table Package NDC Product Description Form Quantity Strength SPL version 84651-200-30 IBTROZI 30 in 1 BOTTLE CAPSULE 30 4 84651-200-90 IBTROZI 90 in 1 BOTTLE CAPSULE 90 4 84651-200-90 IBTROZI 1 in 1 CARTON CAPSULE 1 4 84651-200-93 IBTROZI 3 in 1 CARTON CAPSULE 3 4
openFDA label cross-check# OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
Matched openFDA labels page 1 of 1 · 1 matching rows.
DailyMed RxNorm Mappings# Packages# Package NDC, 11-digit format, Description table Package NDC 11-digit format Description Units Marketing start Sample Exclude flag Status 84651-200-93 84651020093 3 BOTTLE in 1 CARTON (84651-200-93) / 30 CAPSULE in 1 BOTTLE (84651-200-30) 3 bottle 2025-06-13 No No Current